878663-13-9

Basic information

• Product Name: (S)-Norfluoxetine
• Synonyms: (S)-Norfluoxetine Phthalimide
• CAS NO: 878663-13-9
• Molecular Formula: C₂₄H₁₈F₃NO₃
• Molecular Weight: 425.3998296
• Product Categories: Amines;Aromatics;Intermediates & Fine Chemicals;Pharmaceuticals
• Mol File: 878663-13-9.mol

Chemical Properties

• Appearance: /
• Storage Temp.: Refrigerator
• Solubility: Chloroform, Dichloromethane, Ethyl Acetate
• CAS DataBase Reference: (S)-Norfluoxetine(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-Norfluoxetine(878663-13-9)
• EPA Substance Registry System: (S)-Norfluoxetine(878663-13-9)

Safety Data

• Hazardous Substances Data: 878663-13-9(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
(S)-Norfluoxetine is used as a potential antidepressant for its ability to inhibit serotonin re-uptake and phosphodiesterase, which can help alleviate symptoms of depression and improve mood regulation.

Upstream product

• 100306-33-0 (1R)-3-chloro-1-phenylpropanol 
• 1074-82-4 potassium phtalimide 
• 114446-51-4 -(-)-1-chloro-3-phenyl-3-<4-(trifluoromethyl)phenoxy>propane 
• 402-45-9 4-hydroxybenzotrifluoride 

Downstream Products

• 878663-17-3 N'-(S)-[1-(1-naphthyl)ethyl]-N-(S)-3-[4-(trifluoromethyl)phenoxy]-3-phenylpropylurea 
• 878663-14-0 C₃₇H₄₂F₃N₃O₄ 
• 126924-38-7 (S)-norfluoxetine 

Relevant articles and documents

Stereoselective inhibition of serotonin re-uptake and phosphodiesterase by dual inhibitors as potential agents for depression

Multi-target compounds where more than one functional activity is incorporated into the same molecule may have advantages in treating disease states. Selective serotonin re-uptake inhibitors (SSRIs)a (i.e., (R)- and (S)-norfluoxetine) were chemically linked to a PDE4 inhibitor via a five carbon bridge. The new dual PDE4 inhibitor/SSRIs (i.e., (R)-8 and (S)-8) showed moderately potent but highly selective serotonin re-uptake inhibition (IC50 values of 173 and 42 nM, respectively) in vitro. The dual PDE4 inhibitor/SSRIs (R)-8 and (S)-8 also inhibited PDE4D2 (i.e., Ki values of 106 and 253 nM, respectively). Due to the synergistic functional activity, PDE4 inhibitor/SSRIs may be effective in treating diseases such as depression.